HIPKs: Jack of all trades in basic nuclear activities  by Rinaldo, Cinzia et al.
Biochimica et Biophysica Acta 1783 (2008) 2124–2129
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrReview
HIPKs: Jack of all trades in basic nuclear activities
Cinzia Rinaldo, Francesca Siepi, Andrea Prodosmo, Silvia Soddu ⁎
Department of Experimental Oncology, Regina Elena Cancer Institute, 00158 Rome, Italy⁎ Corresponding author. Regina Elena Cancer Institu
00158 Rome, Italy. Tel.: +39 065260 2492; fax: +39 06 5
E-mail address: soddu@ifo.it (S. Soddu).
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.06.006a b s t r a c ta r t i c l e i n f oArticle history: Over the past decade seve
Received 24 April 2008
Received in revised form 26 May 2008
Accepted 10 June 2008







DNA-damage responseral investigators have reported on the physical interaction of serine/threonine
kinases of the homeodomain interacting-protein family (HIPKs) with increasing number of nuclear factors
and on their localization in different nuclear sub-compartments. Although we are still far from a global
understanding of the molecular consequences of HIPK subnuclear compartmentalization, the spatial
description of particular interactions and posttranslational modiﬁcations promoted by these kinases on key
cellular regulators might provide relevant insights. Here we will discuss the possible implications of the HIPK
subnuclear localization in the regulation of gene transcription and in the cell response to stress.
© 2008 Elsevier B.V. All rights reserved.The nucleus of eukaryotic cells is delimited by the nuclear
envelope and harbors DNA associated activities like gene expression,
replication, recombination and repair, as well as RNA processing and
ribosome subunit assembly. These events are regulated by the (epi)
genome, through histone methylation/acetylation or DNA methyla-
tion, and the proteome, through differential expression of speciﬁc
transcription factors and co-factors. In addition, the complex dynamic,
spatial, and temporal organization of proteins and nucleic acids in the
nucleus is regarded as a further control layer for nuclear functions
[reviewed in [1]. Various nuclear sub-compartments have been
described and deﬁned as heterogeneous groups of nucleoplasmic
structures, situated within the nuclear matrix, “scaffold”, and
distinguished mainly by morphologic (ultrastructural) and antigenic
criteria [reviewed in [2]. Nuclear sub-compartments include the
nuclear membrane itself with the nuclear pore complexes, nucleolus,
perinucleolar and perichromatin regions [3], diverse transcription
complexes and replication factories [4] including the AML1 complex
[5] and the polycomb group (PcG) bodies [6], nuclear speckles (also
named SC35 domains) [7], Cajal-bodies (CBs; also named coiled
bodies) [8], and promyelocytic leukemia nuclear bodies [PML-NBs,
also named PML oncogenic dots (PODs), ND10, Kr-bodies] [9].
Recently, HIPK nuclear deposition sites (NUDES) or HIPK domains,
characterized by the presence of HIPKs and the absence of antigens
speciﬁc for other nuclear sub-compartments have been also described
[10,11]. It is argued that all these structures operate in a coordinated
fashion that involves signalingmechanisms using intranuclear kinases
and phosphatases, phosphoinositides, and cytoskeletal proteins. Thete, Via delle Messi d'Oro 156,
266 2505.
l rights reserved.posttranslational modiﬁcations of mRNAs and proteins are emerging
as important regulatory mechanisms in the biology of nuclear sub-
compartments. These modiﬁcations can dramatically change the
localization of molecules and concomitantly modify the structure/
function of nuclear sub-compartments [12].
HIPKs are a family of four serine/threonine kinases (HIPK1–4)
highly conserved in vertebrates. HIPK1–3 were originally discovered
by their ability to bind homeobox factors [13] while HIPK4 was
identiﬁed by the human genome sequence based on the high
homology with the other three members [14]. An increasing number
of screenings for the identiﬁcation of novel protein–protein interac-
tions and the consequent functional studies have indicated HIPKs, and
particularly HIPK2, as a “versatile switchboard” that contributes to the
regulation of remarkably diverse nuclear pathways involved in gene
transcription, cell survival, proliferation, response to DNA damage,
differentiation, and development [15,16]. Interestingly, HIPKs' activ-
ities are associated with particular subnuclear distribution of these
kinases and of their targets. Here, we will focus our attention on the
emerging role(s) played by the HIPK family members in the biology of
diverse nuclear sub-compartments. We are far from a clear under-
standing of the biological activities HIPKsmight take part in; however,
the increasing number of partners bound, posttranslationally mod-
iﬁed, and relocalized within nuclear sub-compartments by HIPKs
certainly justiﬁes a revision of our current knowledge on this
emerging topic.
1. HIPKs subcellular localization
HIPKs were originally deﬁned, based on the structure of the ﬁrst
three proteins identiﬁed (HIPK1, HIPK2, and HIPK3), as nuclear serine/
threonine kinases characterized by the presence of a kinase domain in
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central portion of the protein, a speckle-retention signals (SRS)
superimposed to a PEST region, and a YH reach region in the C-
terminal portion [13,15,16]. The kinase domain and the PEST region are
present in all four members of the family while the homeobox-
interacting domain is absent in the more recently identiﬁed member,
HIPK4 (Fig. 1), which is mainly expressed in the cytoplasm, making it
possible that HIPK4 is a member of an independent protein kinase
family [17]. Thus, for the purpose of this review, we will concentrate
on the ﬁrst three members, HIPK1, HIPK2, and HIPK3, here collectively
named HIPKs.
Several studies have analyzed the localization of HIPKs upon
overexpression of their chimeric forms with different tags, such as
GFP, Flag, HA, or Myc in human or mouse cells [11,13,18,19]. These
experiments consistently showed a mostly nuclear dotted localization
of HIPK1–3, the so called speckles, and a milder and diffuse
cytoplasmic staining. The nuclear localization might be regulated by
the in silico deﬁned nuclear localization signals (NLS) as well as by the
presence of the putative SRS in the C-terminal region of the proteins
(Fig. 1). Indeed, in the HIPK2 protein, deletion of the SRS region
impairs the nuclear dottedmorphology of the kinasewithout affecting
its presence in the nucleus, supporting the involvement of the SRS in
the speckled localization [11,13]. Canonical SRSs [20] are required for
directing proteins to nuclear speckles or SC35 domains, which are
nuclear organelles that are enriched in splicing snRNPs and many
other transcription and splicing-related proteins. They also contain
speckle-associated proteins, amongwith ser/thr kinases that by serine
phosphorylation of serine/arginine-rich (SR) proteins control both
their association with the spliceosome and their recruitment from
speckles to active sites of transcription [12]. The amino acid sequence
of the HIPK SRS differs among the HIPKs and from the canonical
sequences suggesting that the HIPK speckles are different from theFig. 1. Schematic representation of HIPK proteins (Swissprot Q9QZR5). KD is the kinase
domain; HID is the homeobox-interacting domain; PEST is the PEST-sequence
containing region that overlaps with the speckle-retention signal (SRS); D916 and
D977 are the caspase-cleavage sites, as indicated by the scissors [49]. A putative
caspase-cleavage site, D940, is present in HIPK1 but whether this kinase is cleaved by
caspases is still unknown. The sites at the N-terminus of HIPK1–3 sumoylated with
SUMO-1 are indicated. K1182 of mouse HIPK2 is ubiquitylated by MDM2 [50]. The C-
terminal region of this kinase is also ubiquitylated by WD40 repeat/SOCS box protein
WSB-1, but the lysine residue(s) involved is presently unknown [51]. The pick triangles
in HIPK2 indicate the putative NLS reported by Kim et al. [13] while the asterisks (⁎)
indicate the sorting signals that predict nuclear localization by the PSORT program [52].
Substitution of K825 (the red K) with alanine did not modify the nuclear localization of
HIPK2 (C.R. unpublished results).SC35 domains. However, direct experiments to verify whether the
HIPK speckles co-localize with the SC35 domains have not been
reported yet. In addition, we have to take into consideration that the
putative HIPKs' SRS overlaps with the region implicated in the HIPKs
binding with most of the non-homeobox proteins that have been
found thus far to interact with HIPK1–3 andwhose co-expressionwith
the kinases in co-transfection experiments promoted the redistribu-
tion of HIPK partners in the HIPK-containing speckles (see below for
detailed interactions). Based on these results, we cannot exclude that
the absence of HIPK localization in the nuclear speckles observed in
the absence of the SRS region depends on the loss of protein–protein
interaction rather than on the loss of a speciﬁc localization signal.
Further analyses with more restrained HIPK mutants are required to
solve this issue.
The experiments described above were performed with trans-
fected proteins and their results might be artiﬁcial. This possible pitfall
has been overcome, at least for HIPK1 and HIPK2, since the subcellular
localization of their endogenous forms has been studied with speciﬁc
antibodies in human and mouse cells. The Schmitz's group analyzed
the localization of endogenous HIPK2 in human U2OS osteosarcoma
cells and observed a speckled distribution of this kinase [11,21]. Other
important data on endogenous HIPK1 and HIPK2 were reported by
Isono et al., who examined the expression and localization of both
kinases by double immunostaining in primary mouse embryo
ﬁbroblasts (MEFs) from 12.5 day post-coitus fetuses. HIPK1 and
HIPK2 were found co-expressed in the same cells and both proteins
had a speckled staining throughout the nucleus apart from the
nucleoles. Speckles were composed of a central condensed region
surrounded by a less-condensed, foggy area. Interestingly, the
condensed speckles for HIPK1 and HIPK2 were mostly separated
with limited overlap. This particular distribution was not maintained
in overexpressing conditions that rather showed a strong co-
localization of the HIPK1 and HIPK2 speckles [22]. The latter result
is similar to the observationmade by co-transfecting HIPK2 and HIPK3
[11] and strongly suggests the existence of a dynamic redistribution of
the HIPKs within the nucleus and among diverse nuclear sub-
compartments in different cellular conditions. Probably, overexpres-
sion of the kinases is mimicking cell stress and therefore these results
should be taken with caution.
2. HIPKs and the PML-NBs
The type of distribution and the shape of HIPK accumulations have
stimulated the analysis of their possible co-localization with similar
shaped nuclear sub-compartments. The ﬁrst indication in this regard
came from the observation that HIPK2 can bind the tumor suppressor
p53 and co-localize with it in the PML-NBs (Fig. 2) [21,23].
The PML-NBs are functionally versatile nuclear structures inwhich
permanently or transiently localize a large number of cellular proteins
whose proper assembly is dictated by the PML tumor suppressor
protein. These NBs have a “doughnut-like” structure, do not contain
detectable nucleic acids but make extensive contacts with chromatin.
At the molecular levels, the contribution of PML-NBs has been
summarized as follow: i) identiﬁcation and storage of proteins; ii)
posttranslational modiﬁcation of proteins; iii) transcriptional regula-
tion; iv) chromatin organization. At the functional level, PML-NBs
have been implicated in the regulation of several biological events as
diverse as DNA-damage response, apoptosis, senescence, and angio-
genesis [reviewed in [9].
The p53 tumor suppressor functions as a master regulator of cell
response to several types of stress including DNA damage and
oncogenic stimuli. To exert these functions, the latent p53 protein,
constitutively expressed in an inactive state, is stabilized and activated
[24]. These events are thought to depend largely on posttranslational
modiﬁcations and protein/protein interactions with an increasing
array of co-factors that regulate the p53 response at a multiplicity of
Fig. 2. Schematic representation of the interactions among HIPK2 or HIPK1 and several of their partners, which have been observed to localize to PML-NBs, at least in overexpression.
Callouts report the functional outcomes described for the indicated interactions. The arrows indicated the release from the PML-NBs of the indicated proteins.
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thought to provide a “platform” favoring p53 interaction with speciﬁc
enzymes [26]. HIPK2 was shown to be one of such enzyme that binds
to and activates p53 by speciﬁcally phosphorylating it at Ser46 and by
promoting the interaction between p53 and the CREB-binding protein
(CBP) that acetylates p53 at Lys382 [21,23]. In addition, p53Ser46
phosphorylation was shown to trigger the interaction of p53 with the
prolyl-isomerase Pin1, whichmediates p53 conformational changes as
well as p53 dissociation from the apoptosis inhibitor iASPP [27,28]. All
these events are required for efﬁcient loading of p53 on speciﬁc target
promoters upon stress. Based on these different observations, it has
been proposed that HIPK2 might be the trigger of a chain of events
that from p53 phosphorylation at Ser46 move to Pin1 modiﬁcation,
CBP and p300 recruitment, p53 acetylation at Lys382, iASPP detach-
ment and speciﬁc transcriptional activation [26,28]. Answers in need:
up to now, it is not clear whether all these events take placewithin the
PML-NBs, what kind of event activates HIPK2, and where it happens:
outside or inside the PML-NBs. What we have learned thus far, is that
among the seven PML isoforms, PML IV (previously named PML-3) is
capable of binding both p53 and HIPK2 and is required for HIPK2-
mediated p53Ser46 phosphorylation and activation of p53-dependent
transcription. Indeed, in PML−/− MEFs, overexpression of PML IV, but
not of PML III, recruits HIPK2 to PML-NBs and is essential for HIPK2-
mediated p53Ser46 phosphorylation and activation of p53-dependent
transcription [11].
Although PML IV is required for HIPK2 function at PML-NBs,
several other proteins residing within the PML-NBs have been found
to play a role in the regulation of HIPK2 and HIPK1 in these NBs. Sp100,
one of the permanent residents of PML-NBs, interacts with HIPK2 and
partially co-localizes with this kinase in PML-NBs. This interaction
contributes to the HIPK2-mediated activation of p53, as shown by
depletion of Sp100 expression by RNA interference in human cell lines
[29]. The HIPK2-mediated activation of p53 associated with localiza-
tion to PML-NBs is induced also by proteins, such as the tumor protein
p53-induced nuclear protein 1 (TP53INP1) and the LIM domain
protein FHL2 (four and half LIM 2). Both proteins were found to
interact and co-localize with HIPK2 and enhance HIPK2-mediated,
p53-induced transcriptional activity [30,31].
Other proteins have been found to bind to and co-localize with
HIPK2 in PML-NBs independently from the HIPK2/p53 interaction.These interactors include the centrosomal protein involved in
microtubule nucleation RanBPM [32]; the transcriptional co-repressor
c-Ski [33]; the p53 family members p73α and p63α [34]. However,
whether the functional outcomes of these interactions depend on
their localization at the PML-NBs is still unknown.
The interactions described above, whether demonstrated with the
endogenous proteins or observed only upon overexpression, are
characterized by a common feature: co-expression with one of the
HIPK members promotes/increases the PML-NB localization of the
HIPKs' interactors. A different behavior was observed upon the
interaction between HIPK1 or HIPK2 and Daxx, a death domain-
associated protein. Daxx, originally identiﬁed as an interactor of CD95,
the fas/APO-1 death receptor, was subsequently shown to localize also
in the nucleus, to associate with PML in the PML-NBs and to repress
transcription when released from NBs and relocalized to chromatin
[reviewed in 35]. It has been shown that HIPK1 and HIPK2 promote
Daxx phosphorylation and release from PML-NBs. This process is
dependent on the HIPKs' catalytic activity since the kinase-dead HIPK
mutants are unable to relocalize Daxx [18,36,37]. In addition, the
Daxx-S669A mutant that cannot be phosphorylated by HIPK1, has a
stronger repressing activity on speciﬁc promoters, suggesting that
HIPK1 does not only regulate Daxx localization, but also modulates its
transcriptional repressing function [18]. For Daxx interaction with
HIPK2, no direct phosphorylation could be detected, and activation of
two different pathways has been described. In the ﬁrst case, HIPK2
and Daxx participate in the transforming growth factor β (TGF-β)
signaling pathway and cooperate in the activation of c-Jun NH2-kinase
(JNK) and the induction of apoptosis in a p53-independent manner
[37]. In the second case, Daxx was shown to cooperate with the Axin/
HIPK2/p53 complex in the induction of a p53-dependent apoptosis
[38]. However, it is still unknown whether these two latter pathways
are a consequence of the HIPK-induced Daxx release from PML-NBs or
whether they rely on the presence of HIPKs in other subcellular
compartments.
While the Daxx release from PML-NBs induced by HIPK is probably
involved in cell response to stress, it remains puzzling the observation
made by Engelhardt et al. upon overexpression of hamster HIPK2 [36].
These authors observed not only the release of Daxx from PML-NBs
but a more general reorganization of the entire PML-NBs that
resembles the reorganization occurring in the M phase of the cell
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[9]. It remains to be elucidated whether this effect is linked to hamster
HIPK2 overexpression or it hides a still uncovered function of HIPKs.
3. HIPK-NUDES or HIPK domains
As described above, a portion of the HIPKs speckles observed in the
nucleus of human and mouse cells are PML-NBs, and PML IV is
required for the recruitment of at least HIPK2 in these NBs. However,
the majority of the nuclear HIPK speckles do not co-localize with PML
and exist also in PML−/− MEFs, suggesting the presence of HIPKs in
other nuclear sub-compartments [11].
Co-localization experiments with nucleolus and Cajal body speciﬁc
markers have been performed in human U2OS cells carrying an
exogenous GFP-HIPK2 protein. Since, in similar conditions, the co-
staining with PML revealed a partial co-localization of either HIPK2 or
HIPK3 and the PML-NBs, the remaining speckled structures, in the
absence of any other marker, were deﬁned as HIPK domains [11]. Of
course, this is a temporary deﬁnition waiting for further characteriza-
tion, but it is very useful for reminding us that HIPKs like to have a
speckled localization even when they do not belong to PML-NBs.
An initial characterization of the HIPK domains showed that the
kinase activity of HIPK2 is dispensable for recruitment into the PML-
NBs but is required for speckled localization. Indeed, the kinase-dead
HIPK2-K221Amutant is found in the nucleoplasmbut does not localize
to speckles [11]. Interestingly, no such delocalizationwas observed for
the HIPK1-K219A and HIPK3-K226S kinase-dead mutants indicating a
different behavior among the family members [18,19].
The C-terminal region of HIPK2 is also required for the formation of
HIPK domains as it is for the presence of HIPK2 in the PML-NBs
[10,11,21]. As described above, the HIPK C-terminal region is involved
in many of the protein/protein interactions, supporting the hypothesis
that the incapacity to aggregate into nuclear sub-compartmentsmight
depend on the incapacity to interact with other proteins.
An interesting aspect on the HIPK domains regards the HIPK2-
mediated activation of the p53 pathway. It has been shown that HIPK2
can phosphorylate p53Ser46, promote p53 acetylation, stimulate p53-
mediated transcription and inhibit colony formation only in PML+/+
MEFs, while these functions are completely lost in PML−/− MEFs,
despite the maintenance of HIPK domains. These data indicate that,
the existence of HIPK domains is not sufﬁcient for activation of the
p53-dependent functions of HIPK2 [11]. Although it is tempting to
hypothesize that HIPK domains function as a reservoir of inactive
HIPKs that can be relocalized to PML-NBs, or other nuclear sub-
compartments when required, recent interesting data indicate that at
least part of the HIPK domains correspond to the polycomb group
(PcG) bodies and are required for transcription repression (see below)
[39].
4. HIPKs, SUMO, and the PcG bodies
Small ubiquitin-like modiﬁer-1 (SUMO-1) is a member of a
growing family of ubiquitin-related polypeptides. The enzyme con-Fig. 3. Schematic representation of the progressive activation of HIPK2 and Pc2 in the PcG b
phosphorylation which, in turn, promotes its own sumoylation as well as sumoylation of Hjugation system for SUMO is similar to that of ubiquitin but
sumoylation is involved in more diverse functions than ubiquitylation,
which is mainly used, though non exclusively, for protein degrada-
tions. Indeed, sumoylation was shown to participate in nuclear
transport, protein stabilization, transcription regulation, or PML-NBs
formation [40,41]. HIPKs are sumoylated with SUMO-1 but not SUMO-
2 or SUMO-3 [42] in their N-terminal regions at an evolutionary
conserved site (Fig. 1) by the ubiquitin-like protein conjugating (E2)
enzyme UBC9 [10] and the polycomb group (PcG) SUMO (E3) ligase
Pc2 [39]. The sumoylation per se does not change the subnuclear
localization of HIPKs [42,43], as originally proposed by Kim et al. based
on their observations that HIPK2 deletion mutants not interacting
with UBC9 no longer localize to nuclear speckles [10]. At the functional
level, sumoylation does not change the ability of HIPK2 tomediate p53
activation but does modify the HIPK2 co-repressor activity with
Groucho or the HIPK2-mediated, TGF-β-induced activation of JNK
[42–44] suggesting that sumoylation might be involved in conferring
speciﬁcity to HIPK2 functions. This modulation can be further
enriched by the activity of different SUMO deconjugating enzymes,
some of which have been already reported to bind and desumoylate
HIPK1 and HIPK2 [42,45,46].
Thus far, the most intriguing data on HIPK sumoylation come
from the work of Roscic et al. [39]. Starting from a yeast two-hybrid
screening for HIPK2 interactors, the authors have shown that the Pc2
SUMO E3 ligase binds to and co-localizes with HIPK2, that HIPK
domains largely overlap with PcG bodies and that their formation
depends on both HIPK2 sumoylation and kinase activity. Based on
the reciprocal localization of HIPK2 and Pc2, three different classes of
speckles can be morphologically deﬁned. As summarized in Fig. 3,
upon DNA damage, activated HIPK2 phosphorylates Pc2 at multiple
sites including Thr495, which is required to increase the ability of
Pc2 to sumoylate itself and HIPK2. In turn, this sumoylation increases
the HIPK2 activity to repress transcription [15,39]. These data
provide an interesting mechanistic clue on the general transcrip-
tional silencing induced by DNA damage and spatially distinguish
this event (p53-independent and localized to PcG body) from the
transcriptional activation of apoptotic genes (p53-dependent and
localized to PML-NB).
5. HIPKs and the AML1 transcription factor complex
AML1 is a transcription factor originally identiﬁed at a breakpoint
of chromosome 21 translocation present in acute myeloid leukemia
(AML). AML1 forms large multiprotein complexes including core
binding factor (CBF)β as “core component” and several other
chromatin modulators such as CBP/p300, PML, monocytic leukemia
zinc ﬁnger protein (MOZ), and HIPK2. These complexes bind to
speciﬁc DNA sequences to activate or repress transcription of genes
involved in the development and differentiation of hematopoietic
lineages, and a role as chromatin regulatory factories ﬁne-tuned by
protein–protein interactions has been proposed [5].
The presence of HIPK2 in AML1 complexes has been ﬁrst detected
by LC/MS/MS analysis. HIPK2 binds AML1b and p300 and phosphor-odies. After DNA damage, the ﬁrst step of HIPK2 activation (still unknown) induces Pc2
IPK2 that induces transcriptional repression.
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In the case of AML1b, Ser249 and Ser276 have been identiﬁed as direct
HIPK2 targets. MOZ phosphorylation requires the presence of both
AML1 and HIPK2 and is followed by an increased stabilization of the
AML1/MOZ complexes. Finally, HIPK2-induced phosphorylation of
p300 depends on AML1 phosphorylation since the non-phosphor-
ylatable AML1-S249A/S276A mutant does not cooperate with HIPK2
in the phosphorylation of p300 and the subsequent transcriptional
activation [47]. Interestingly, highly phosphorylated forms of p300 are
rare in Hipk1/Hipk2 double knock-out embryos, which die between
E9.5 and E12.5 with defects in vascular-genesis, angiogenesis, and
hematopoiesis. Similar behaviors were reported in p300 and CBP-
deﬁcient mice [47].
Recently, two missense mutations of HIPK2 (R868W and N958I)
have been identiﬁed in a screening of 50 cases of AML and 80 cases of
myelodysplastic syndrome (MDS), a pre-leukemia syndrome [48]. The
two mutations are located within the SRS region (Fig. 1) and modify
the subnuclear localization of the kinase. Indeed, expression of HA-
tagged HIPK2 wild-type and mutant proteins in U2OS cells resulted in
a nuclear localization of all three proteins. However, both HIPK2
mutants i) have lost the typical, small speckled distribution; ii) exhibit
conical or ring-shaped particles distributed throughout the nucleus;
iii) no longer co-localize with AML-1 and p300 although they
maintain the capacity to bind and phosphorylate these proteins in
vitro; iv) no longer stimulate AML1-mediated, p300-mediated, and
p53-mediated transcriptional activity [49]. For the future, it will be
interesting to evaluate whether these mutants interfere also with the
biology of PML-NBs, whether the reduced p53 transcriptional activity
is due to a reduction in p53Ser46 phosphorylation and whether
leukemia cells carrying these mutants are more resistant to chemo-
therapy or radiotherapy.
6. Conclusion
The ten years that have passed since the discovery of the HIPK
family have resulted in the identiﬁcation of a still enlarging body of
HIPK's targets and partners. By virtue of protein/protein interaction
and phosphorylation of speciﬁc serine/threonine residues, HIPKswere
shown to be involved in the regulation of gene transcription and
response to DNA damage. A diverse and probably dynamic nuclear
sub-compartmentalization has added a further level of complexity
that we just begin to understand in the activity of these kinases. In the
future, immunochemical analysis of the subnuclear redistribution of
endogenous HIPKs in diverse cellular conditions in vitro and in vivo,
the study of protein composition of the HIPK-containing subnuclear
organelles by performing mass spectrometry on biochemically
fractionated nuclei, as well as in vivo imaging analyses of inducible
GFP-HIPK-chimeras will certainly help in revealing the contribution of
HIPKs to the dynamic interactions that govern organization and
activities of the nuclear sub-compartments.
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